A Phase 4 interventional study of Teneligliptin and Linagliptin in Type2 Diabetes Mellitus, sponsored by Handok Inc.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2019-02-22.
Sponsored by Handok Inc. · Phase 4, Interventional, and Treatment
To assess the efficacy and safety of Teneligliptin and Linagliptin in the type 2 Diabetes Mellitus patients.
A randomized, open label, parallel-group, non-inferiority, active-controlled, phase IV study
Handok Inc. is the lead sponsor of 46 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
teneligliptin 20mg qd
Drug: Teneligliptin
linagliptin 5mg qd
Drug: Linagliptin
teneligliptin 20mg qd
linagliptin 5mg qd
HbA1c
Time frame: 12week
Ran from Jan 2017 to primary completion in Sep 2018, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teneligliptin